Add On Effect Of Basti In Non-Alcoholic Fatty Liver Disease.

Evaluating Clinical Efficacy Of Add On Effect Of Basti In Non-Alcoholic Fatty Liver Disease Based On Sonographic Findings. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064543

Enrollment

Registered

2024-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Previously diagnosed and newly diagnosed case of NAFLD (fatty liver grade 1 or 2) confirmed by Sonography (USG Or Fibroscan) 2.Grade 1 & Grade 2 NAFLD in USG Or F0 to F2 Less Than 10kPa Score,CAP Score -S1 248-260db per m,S2 260-290 db per m,IQR per M-30 Percent or less in Fibroscan. 3.Patients willing to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: 1.Patent having NASH/NAFLD associated with Metabolic diseases 2. Patients having NAFLD Grade 3 Or More 3. Patients with Type 2 diabetes 4. Known case of Hypertension 5. Known case of hypothyroidism or hyperthyroidism 6. Patients having BMI Greater than 30, 7. Patients having deranged liver functions (AST per ALT Greater than 2 folds). Patients suffering from Hepatitis, Cirrhosis of liver, Ascites, Portal hypertension (PTH), patient having other chronic liver diseases, etc. 8. Patients having deranged renal functions Or chronic kidney diseases. 9. Patients suffering from AIDS, Tuberculosis and other infectious diseases. 10. Any Malignancy. 11. Pregnant and lactating women. 12. Patient on long term medication (Hepatotoxic medication like NSAID, Rifampicin,steroid). 13. Patients consuming Alcohol or other narcotic substance.

Design outcomes

Primary

Measure	Time frame
Changes In Sonography Findings (Expecting From Grade II To Grade I Or 0 And From Grade I To Grade 0) Along With Changes In Clinical Presentations (Expecting 5% To 10% Reductions In Signs And Symptoms).Timepoint: Day 1 30 Days 60 Days	—

Secondary

Measure	Time frame
1 Changes In Waist Circumference 2 Changes In Liver Function Tests 3 Changes In Lipid Profile 4 Changes In Vitamin D Level 5 Improvement In Quality Of Life.Timepoint: Day 1 Day 30 Day 60	—

Countries

India

Contacts

Public ContactDr Kachchhi Gopi Ashvinbhai

All India Institute Of Ayurveda

divyakajaria@gmail.com8826167515

Outcome results